Spectrum Pharma To Restructure Organization; To Cut Workforce By Approx. 30%

By RTTNews Staff Writer ✉ | Published: 1/5/2022 8:26 AM ET

Spectrum Pharmaceuticals (SPPI) announced a strategic restructuring, which will result in a workforce reduction of approximately 30%. The company noted that physical footprint of selected facilities will be significantly reduced in 2022.

Spectrum said the company is prioritizing the development activities for its late-stage
assets, poziotinib and ROLONTIS, and will deprioritize work on its early-stage
pipeline, FIT Program and IL-12.

Tom Riga, CEO, Spectrum Pharmaceuticals, said: "The changes we are implementing
are expected to result in a reduction in operating expenses and the extension
of the company's cash runway into 2023."

For comments and feedback contact: editorial@rttnews.com

Business News

Biotech Stocks Facing FDA Decision In March 2023

Biotech Stocks Facing FDA Decision In February 2023

Biotech stocks Facing FDA Decision in January 2023

Editors Pick

United Airlines, Archer To Launch First Air Taxi Route In Chicago

United Airlines and Archer Aviation Inc. announced plans to launch the first commercial electric air taxi route in Chicago, between O'Hare International Airport or ORD and Vertiport Chicago. As part of their urban air mobility or UAM network buildout, both companies will utilize Archer's electric vertical takeoff and landing or eVTOL aircraft in the new route.

Aunt Millie's Our Family White Hot Dog Buns Recalled

Fort Wayne, Indiana-based Perfection Bakeries D/B/A Aunt Millie's is recalling 8 ct. packages of Our Family White Hot Dog Buns citing the possible presence of undeclared sesame, a known allergen, the U.S. Food and Drug Administration said. The product comes in a printed plastic package marked with "Our Family Hot Dog Buns 8 ct." on the top and has a blue twist tie.

Ascend Labs Recalls Oral Anticoagulant Dabigatran Etexilate Capsules

Parsippany, New Jersey -based Ascend Laboratories LLC. is recalling Dabigatran Etcxilate capsules citing the detection of N-Nitrosodimethylamine or NDMA impurity, a probable human carcinogen, the U.S. Food and Drug Administration said. The product is used as an oral anticoagulant to lower the risk of stroke and blood clots.